Adocia announces the signature of a liquidity agreement with Kepler Capital Markets SA

**Lyon, France, May 19, 2014** - Adocia (Euronext Paris: FR0011184241 – ADOC) announces that it signed a liquidity agreement on May 19, 2014 with Kepler Capital Markets SA.

This liquidity agreement, complying with the charter of ethics established by the French Financial Markets Association (A.M.A.F.I.) as recognized by the French market authority (Autorité des marchés financiers) will be effective as of May 20, 2014 before market open until December 31, 2014, it being thereafter tacitly renewable for successive periods of one year.

For the implementation of this liquidity agreement, the following resources have been allocated to the liquidity account:

- 15,026 Adocia shares, and
- 300,000 euros in cash.

Adocia terminated on April 30, 2014 the liquidity agreement entered into with DSF MARKETS.

**About Adocia:**

**To be a global leader in the delivery of insulins and therapeutic proteins**

Adocia is clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia’s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

Adocia has successfully completed two Phase I and II studies of a fast-acting human insulin formulation, two Phase I and II studies of an ultra-fast-acting insulin lispro and a Phase I/II of a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. Dose-escalation Phase IIa studies of all three products are scheduled for 2014.

The company has also obtained positive results in a Phase I/II study of a diabetic-foot-ulcer-healing product based on PDGF-BB (Platelet-Derived Growth-Factor BB). A phase III clinical trial dossier has been filed with Indian regulatory authorities, and the trial is expected to start in 2014.
Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field.

**Fighting cancer with targeted treatments**

DriveIn® is a nanotechnology which is remarkably efficient in delivering active compounds into cancer cells. This new platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

"**Innovative medicine for everyone, everywhere**"

Adocia’s therapeutic innovations aim at providing solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and its share price is included in the Next Biotech index.

For more information, visit [www.adocia.com](http://www.adocia.com)

---

**Contact**
**Gerard Soula** - contactinvestisseurs@adocia.com
Chairman and CEO, Adocia
Tel.: +33 472 610 610

**Press Relations**
**ALIZE RP**
Caroline Carmagnol /Sayuli Nishioka
alizerp.com – sayuli@alizerp.com
Tel.: +33 170 225 390